JPWO2021005338A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021005338A5 JPWO2021005338A5 JP2022500119A JP2022500119A JPWO2021005338A5 JP WO2021005338 A5 JPWO2021005338 A5 JP WO2021005338A5 JP 2022500119 A JP2022500119 A JP 2022500119A JP 2022500119 A JP2022500119 A JP 2022500119A JP WO2021005338 A5 JPWO2021005338 A5 JP WO2021005338A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- cell
- nucleic acid
- antigen
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025076885A JP2025124655A (ja) | 2019-07-05 | 2025-05-02 | 新規な癌抗原及び方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19184680.7 | 2019-07-05 | ||
| EP19184680 | 2019-07-05 | ||
| EP20170224 | 2020-04-17 | ||
| EP20170224.8 | 2020-04-17 | ||
| PCT/GB2020/051592 WO2021005338A2 (en) | 2019-07-05 | 2020-07-03 | Novel cancer antigens and methods |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025076885A Division JP2025124655A (ja) | 2019-07-05 | 2025-05-02 | 新規な癌抗原及び方法 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022540396A JP2022540396A (ja) | 2022-09-15 |
| JP2022540396A5 JP2022540396A5 (https=) | 2023-07-11 |
| JPWO2021005338A5 true JPWO2021005338A5 (https=) | 2023-07-11 |
| JP7751817B2 JP7751817B2 (ja) | 2025-10-09 |
Family
ID=71523190
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022500119A Active JP7751817B2 (ja) | 2019-07-05 | 2020-07-03 | 新規な癌抗原及び方法 |
| JP2025076885A Pending JP2025124655A (ja) | 2019-07-05 | 2025-05-02 | 新規な癌抗原及び方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025076885A Pending JP2025124655A (ja) | 2019-07-05 | 2025-05-02 | 新規な癌抗原及び方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220213159A1 (https=) |
| EP (1) | EP3993826B1 (https=) |
| JP (2) | JP7751817B2 (https=) |
| KR (1) | KR20220034040A (https=) |
| CN (1) | CN114206913A (https=) |
| AU (1) | AU2020309202A1 (https=) |
| BR (1) | BR112022000020A2 (https=) |
| CA (1) | CA3142329A1 (https=) |
| IL (1) | IL289335A (https=) |
| MX (1) | MX2022000263A (https=) |
| WO (1) | WO2021005338A2 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112021006941A2 (pt) | 2018-10-19 | 2021-08-31 | The Francis Crick Institute Limited | Antígenos de câncer inovadores e métodos |
| CN116057067A (zh) * | 2020-04-17 | 2023-05-02 | 弗朗西斯·克里克研究所有限公司 | 用于治疗黑素瘤的ctl抗原的融合蛋白 |
| JP2023522193A (ja) * | 2020-04-17 | 2023-05-29 | ザ フランシス クリック インスティチュート リミティッド | 抗原プール |
| WO2025202937A1 (en) | 2024-03-26 | 2025-10-02 | BioNTech SE | Cancer vaccines |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002515734A (ja) | 1996-01-02 | 2002-05-28 | カイロン コーポレイション | 遺伝子改変された樹状細胞により媒介される免疫刺激 |
| US6770456B1 (en) | 1998-07-29 | 2004-08-03 | Ludwig Institute For Cancer Research | Endogenous retrovirus tumor associated nucleic acids and antigens |
| EP1586330A1 (en) | 2004-04-16 | 2005-10-19 | Georg-August-Universität Göttingen | Vaccination against malignant melanoma |
| DK1871391T3 (da) | 2005-03-30 | 2012-04-16 | Viroxis | Endogen retrovirus og proteiner, der kodes af env som target for cancerbehandling |
| WO2006105642A1 (en) * | 2005-04-05 | 2006-10-12 | British Columbia Cancer Agency | Biomarkers for the detection of lung cancer and uses thereof |
| AT502292B1 (de) * | 2005-05-11 | 2010-04-15 | Avir Green Hills Biotechnology | Melanomdiagnose |
| US8921050B2 (en) | 2006-03-17 | 2014-12-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of diagnosing renal cell carcinoma |
| US20080019979A1 (en) | 2006-05-22 | 2008-01-24 | Feng Wang-Johanning | HERV-K Antigens, Antibodies, and Methods |
| US8541553B2 (en) * | 2007-05-24 | 2013-09-24 | Baxter Healthcare Sa | Antibodies specific for the melanoma-associated endogenous retrovirus (MERV) envelope glycoprotein |
| TW201326481A (zh) * | 2011-08-30 | 2013-07-01 | Nat Defense Medical Ct | 預測易罹患卵巢贅瘤或卵巢癌預後之生物標記 |
| AU2018394238A1 (en) * | 2017-12-28 | 2020-06-18 | Lonza Sales Ag | Exosomes for immuno-oncology and anti-inflammatory therapy |
| CN116057067A (zh) * | 2020-04-17 | 2023-05-02 | 弗朗西斯·克里克研究所有限公司 | 用于治疗黑素瘤的ctl抗原的融合蛋白 |
-
2020
- 2020-07-03 WO PCT/GB2020/051592 patent/WO2021005338A2/en not_active Ceased
- 2020-07-03 MX MX2022000263A patent/MX2022000263A/es unknown
- 2020-07-03 KR KR1020217040819A patent/KR20220034040A/ko not_active Ceased
- 2020-07-03 CN CN202080049314.4A patent/CN114206913A/zh active Pending
- 2020-07-03 JP JP2022500119A patent/JP7751817B2/ja active Active
- 2020-07-03 CA CA3142329A patent/CA3142329A1/en active Pending
- 2020-07-03 EP EP20737269.9A patent/EP3993826B1/en active Active
- 2020-07-03 AU AU2020309202A patent/AU2020309202A1/en not_active Abandoned
- 2020-07-03 BR BR112022000020A patent/BR112022000020A2/pt not_active IP Right Cessation
-
2021
- 2021-12-17 US US17/644,938 patent/US20220213159A1/en active Pending
- 2021-12-23 IL IL289335A patent/IL289335A/en unknown
-
2025
- 2025-05-02 JP JP2025076885A patent/JP2025124655A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Liu et al. | Cancer vaccines as promising immuno-therapeutics: platforms and current progress | |
| Molino et al. | Viral-mimicking protein nanoparticle vaccine for eliciting anti-tumor responses | |
| JP5127224B2 (ja) | 予防又は治療目的のためのｍｈｃクラスｉ拘束性エピトープに対する免疫応答を誘発し、増強し、維持する方法 | |
| JP5709264B2 (ja) | ワクチン組成物および方法 | |
| CN115845040A (zh) | 用于免疫疗法的核/壳结构平台 | |
| JP2006523688A (ja) | ヌクレオチド・ワクチン組成、ヌクレオチド及び細胞ワクチン組成の産出方法、ワクチン組成、ワクチン組成使用、免疫反応産出方法、疾患の治療または予防方法、抗原提示細胞から成るキット | |
| JP2001524928A (ja) | クロスプライミング免疫による天然抗原に特異性を有するｃｔｌの誘導 | |
| AU2015233542B2 (en) | A medicament for use in a method of inducing or extending a cellular cytotoxic immune response | |
| Shae et al. | At the bench: Engineering the next generation of cancer vaccines | |
| CN101146550A (zh) | 用于预防或治疗目的的激发、增强和维持对i类mhc-限制性表位的免疫应答的方法 | |
| JP2018528960A5 (https=) | ||
| Nencioni et al. | Anticancer vaccination strategies | |
| JPWO2021005338A5 (https=) | ||
| Errington et al. | Allogeneic tumor cells expressing fusogenic membrane glycoproteins as a platform for clinical cancer immunotherapy. | |
| JPWO2020260897A5 (https=) | ||
| JPWO2021005339A5 (https=) | ||
| AU2014361788B2 (en) | Multi-epitope TARP peptide vaccine and uses thereof | |
| JPWO2020079448A5 (https=) | ||
| Huang et al. | Reprogramming the genome of M13 bacteriophage for all-in-one personalized cancer vaccine | |
| CN112011833A (zh) | 筛选和分离肿瘤新生抗原的方法 | |
| JP2022542320A (ja) | ペプチドがロードされたキャリアシステムおよびその使用 | |
| JP6636915B2 (ja) | ユビキチニル化タンパク質 | |
| Ordaz et al. | DC-expressed MHC class I single-chain trimer-based vaccines prime cytotoxic T lymphocytes against exogenous but not endogenous antigens | |
| Draganov et al. | 290 Cytokine and immune subset signatures in patients with various solid and hematological malignancies treated with oncolytic vaccinia virus delivered by autologous stromal vascular fraction cells | |
| Luo et al. | Emerging strategies for advancing peptide vaccines |